Peter Diamandis - 21 Jun 2022 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role: Director
Signature: /s/ Rene Paula Molina, attorney-in-fact for Peter Diamandis
Issuer symbol: VAXX
Transactions as of: 21 Jun 2022
Transactions value $: $0
Form type: 4
Filing time: 23 Jun 2022, 19:58:27 UTC
Previous filing: 23 Jun 2022
Next filing: 15 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	VAXX	Class A common stock						430,604	21 Jun 2022	Direct
holding	VAXX	Class A common stock						13,824	21 Jun 2022	Held by spouse	F4
holding	VAXX	Class B common stock						1,099,915	21 Jun 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VAXX	Stock option (right to buy)	Award	$0	+129,187		$0	129,187	21 Jun 2022	Class A common stock	129,187	$2.09	Direct	F1, F2, F3
holding	VAXX	Stock option (right to buy)						779,142	21 Jun 2022	Class A common stock	779,142	$1.21	Direct	F5
holding	VAXX	Stock option (right to buy)						528,046	21 Jun 2022	Class A common stock	528,046	$0.5681	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
F2	These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date.
F3	These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
F4	These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest.
F5	Represents 779,142 time-vesting options. These options are subject to a four year vesting schedule, beginning on December 31, 2019, vesting in equal installments each month during the vesting period.
F6	Represents 528,046 time-vesting options. These options are subject to a four-year vesting schedule, with 25% having vested on 6/2/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.